Halolife (Xiamen) Technology Co., Ltd (referred to as Halolife), was established in March 2019. It is an integrated pharmaceutical company which brings together high-tech personnel from home and abroad, and integrates new drug development, process innovation, formulation research and development, registration declaration, production and processing. Halolife has always been tracking the cutting-edge technology of the world's pharmaceutical industry, adhering to the company's tenet of "synchronizing with the world", we focus on the research of drugs that have a profound impact on human health and the development of difficult drugs, in order to fill the domestic gap and participate in the international market competition. Improve the level of the national pharmaceutical industry.
Halolife has successfully developed more than a dozen new drugs in the fields of anti-hepatitis B, anti-hepatitis C, anti-AIDS, anti-tumor, etc. Our products have won the favor of customers in more than 20 countries including Europe, America, Asia and Africa. At present, the company has established a professional research team of 50 persons led by a senior returnee doctor from the United States. It has first-class synthesis, analysis and preparation laboratories, complete pilot workshops and production plants, which can efficiently provide one-stop services from active pharmaceutical ingredients (API), intermediates, small molecule screening, process optimization, and commercial production to the customers all over the world.
